Suven Life Sciences is presenting several data presentations from their portfolio of investigational neuroscience new chemical entitles (NCEs) at SFN 2011 from November 13-16, 2011 being held at Washington DC, USA. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30000 neuro-scientists from all over the world covering all the major pharma, biotech and research institutes are participating.

Suven's nine (9) data presentations cover the early-stage compounds from Histamine-3 receptor antagonist, Nicotinic acetylcholine alpha-4-beta-2 receptor agonist and antagonist, Serotonin 5-HT4 receptor agonist in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer's, schizophrenia, ADHD; depression and mood disorders and neuropathic pain. These data presentation highlights Suven's continued commitment to exploring new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $30 billion.

During SFN-2011 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programmes (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global pharma majors regarding their clinical candidate SUVN-502.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Its discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches.